Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

Eli Lilly revealed major advancements in its alopecia and atopic dermatitis studies, likely driving its 3.77% stock rise. The ...

In UC, Skyrizi faces direct competition from Eli Lilly’s IL-23 inhibitor Omvoh (mirikizumab), approved by the FDA last year, although that isn’t yet approved for Crohn’s disease. The IBD ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...